Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PALACE-1)
This study is ongoing, but not recruiting participants.
Study NCT01172938   Information provided by Celgene Corporation

First Received on July 6, 2010.   Last Updated on February 4, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Psoriatic Arthritis
Additional conditions recognized in this trial
Arthritis
Arthritis, Psoriatic
More general conditions related to this trial
Bone Diseases
Joint Diseases
Musculoskeletal Diseases
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous
Spinal Diseases
Spondylarthritis
Spondylarthropathies
Spondylitis
Interventions listed in this trial
Apremilast 20mg
Apremilast 30mg
Placebo + 20 mg Apremilast
Placebo + 30 mg Apremilast
Additional drug interventions recognized in this trial
Thalidomide
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Celgene Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services